YouTube spreads low-quality medical information on recurrent UTIs, study findsMay 20th 2022
In this interview, coauthors Connie Huang, MD, and Jason M. Kim, MD, discuss the findings of their recent study, "Urinary Tract Infection on social media: Examining YouTube content as a source of patient educational information."
Recent study associates unmet social needs with urologic conditionsMarch 31st 2022
Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence.
Dr. Saad discusses pivotal ARASENS trial for metastatic hormone-sensitive prostate cancerMarch 29th 2022
Urology Times interviewed co-author Fred Saad, MD, FRCS, on the importance of the ARASENS trial and the potential of triplet therapy as the future standard of care for metastatic hormone-sensitive prostate cancer.
Dr. Chai discusses how physicians can resolve imposter syndromeMarch 29th 2022
In this interview, Toby C. Chai, MD, discusses the main takeaways from his presentation on imposter syndrome, personal experiences with imposter syndrome, and ways that physicians can avoid and or/resolve this negative feeling.
How building a social media presence can positively impact your professional developmentMarch 25th 2022
Casey Seideman, MD, advocates for an online presence in a recent presentation given at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference, titled “Social media as an avenue for justice.”
Expert explains significance of PROpel study of olaparib/abiraterone in prostate cancerMarch 24th 2022
In the PROpel study, which was presented at the 2022 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, FRCS, and a team of investigators evaluated the efficacy of olaparib plus abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Dr. Vince discusses how urologists can make “transformative” DEI change within the AUAMarch 24th 2022
In this interview interview, Randy Vince Jr, MD, gives an overview of the article, "A call for change: Why I can’t ‘celebrate’ with the AUA,” and advises fellow urologists on becoming a part of the movement to diversify the field.
Study investigates mindfulness-based stress reduction for urodynamicsMarch 23rd 2022
In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.
Patient counseling in regard to e-cigarettes and erectile dysfunctionMarch 19th 2022
In this interview, Omar El Shahawy, MD, MPH, PhD, discusses patient counseling in regard to e-cigarette use or vaping by using data from a recent study on evaluating the association of e-cigarette use and erectile dysfunction.
Rare diagnosis of penile cancer causes higher mortality rates and stigma, expert saysMarch 18th 2022
Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.
Neoadjuvant nivolumab plus gemcitabine/cisplatin found safe and efficacious in MIBCMarch 16th 2022
The BLASST-1 study presented at the 2022 ASCO Genitourinary Cancers Symposium assessed the safety and efficacy of neoadjuvant nivolumab in combination with gemcitabine/cisplatin in patients with muscle-invasive bladder cancer .
How Botox is changing the landscape of urologic treatmentMarch 14th 2022
Min Dong, PhD, discusses the main points of the presentation he gave at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, along with the potential impact of onabotulinumtoxinA (Botox) therapies on future urologic treatment.
Dr. Nickel discusses saw palmetto as a complementary treatment for LUTSMarch 11th 2022
"We shouldn't outright provide a negative attitude to our patients who are looking for alternatives that [serve as] complementary medicine, [like] herbal or phytotherapeutic agents," says J. Curtis Nickel, MD, FRCSC.
Lutetium-177 PSMA-617 improves symptoms related to bone metastasis in prostate cancerMarch 10th 2022
In this interview, Brian D. Gonzalez, PhD, shares results that were presented at the 2022 ASCO Genitourinary Cancers Symposium from the study, "Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer."
Is neuromodulation beneficial for patients with female sexual dysfunction?March 8th 2022
A study presented at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting evaluated the safety and efficacy of percutaneous tibial nerve stimulation (PTNS) in patients who suffer from female sexual dysfunction.